FDA approves J&J prostate cancer treatment
February 14, 2018 at 13:47 PM EST
Feb 14 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's Erleada treatment for use with prostate cancer patients whose cancer has not spread but continues to grow despite hormone therapy.